Intellia Therapeutics (NTLA) Other Non-Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Other Non-Current Assets data on file, last reported at $1.1 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.1 million, down 64.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 64.82% YoY), and the FY2025 annual result was $978000.0, down 74.18% from the prior year.
• Other Non-Current Assets advanced to $1.1 million in Q1 2026 per NTLA's latest filing, from $978000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $4.5 million in Q4 2023 and troughed at $978000.0 in Q4 2025.
• A 4-year average of $3.0 million and a median of $3.2 million in 2024 frame the typical range for Other Non-Current Assets.
• On a YoY basis, Other Non-Current Assets climbed as much as 10.58% in 2025 and fell as far as 74.18% in 2025.
• A 4-year view of Other Non-Current Assets shows it stood at $4.5 million in 2023, then decreased by 16.16% to $3.8 million in 2024, then plunged by 74.18% to $978000.0 in 2025, then rose by 7.57% to $1.1 million in 2026.
• Business Quant data shows NTLA's Other Non-Current Assets at $1.1 million in Q1 2026, $978000.0 in Q4 2025, and $2.9 million in Q3 2025.